Radiometal-labeled agents (non-technetium) for diagnostic imaging.
Radiometal-labeled agents (non-technetium) for diagnostic imaging.
复制标题
DOI：
10.1002/chin.199947319
复制
发表时间：
1999-08
期刊：
影响因子：
62.1
通讯作者：
C. Anderson;M. Welch
中科院分区：
文献类型：
--
作者：
C. Anderson;M. Welch
使用放射性标记的小复合物和生物分子作为诊断剂是一个相对较新的医学研究领域。在20世纪40年代末和50年代初，核技术开始用于医疗目的，核反应堆，加速器和回旋加速器被应用于医疗同位素生产。1959年，布鲁克海文国家实验室开发了99 Mo/99 mTc发生器，1 1964年，芝加哥大学开发了第一批99 mTc放射性示踪剂。2对99 mTc放射性药物的研究是配位化学研究的开始，因为它与诊断成像有关。尽管99 mTc是用于诊断成像的最广泛使用的放射性核素，3-5已经或正在研究无数其他放射性金属在核医学中的用途。本文就非锝标记的放射性核素标记剂在伽玛射线照相和正电子发射断层扫描（PET）中的应用作一综述。
The use of radiometal-labeled small complexes and biomolecules as diagnostic agents is a relatively new area of medical research. In the late 1940s and early 1950s, the use of nuclear technology for medical purposes began, with nuclear reactors, accelerators, and cyclotrons being applied to medical isotope production. In 1959, Brookhaven National Laboratory developed the 99Mo/99mTc generator,1 and in 1964 the first 99mTc radiotracers were developed at the University of Chicago.2 Research into 99mTc radiopharmaceuticals was the beginning of the study of coordination chemistry as it relates to diagnostic imaging. Although 99mTc is the most widely used radionuclide for diagnostic imaging,3-5 a myriad of other radiometals have been or are being investigated for their uses in nuclear medicine. This review will discuss the non-technetium-labeled radiometal-labeled agents used in gamma scintigraphy and positron emission tomography (PET).